This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05747534 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Massachusetts General Hospital |
| Enrollment | 107 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Long COVID; Long COVID-19; Post Acute COVID-19 Syndrome; Post Acute Sequelae of COVID-19 |
| Interventions | Larazotide Acetate; Placebo |
| Start | May 31, 2023 |
| Primary completion | Jun 18, 2026 |
| Study completion | Jun 18, 2026 |
| Results posted | Not yet |
| Registry last updated | Aug 18, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orally four times a day (QID) for 21 days.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Adverse Event Profiling and Time to Symptom Resolution | 8 weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
